Clinical Trial Update: Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AL8326 for safety and efficacy in second-line or later small cell lung cancer is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• AL8326

Snippet

Sponsor: Advenchen Pharmaceuticals, LLC. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING